Table 1 The characteristics of sarcoidosis in CD patients receiving TNF inhibitor therapy
References | Sex | TNF inhibitor/delay until onset of causative TNF inhibitor (months) | Organs involved | Treatment/outcome | Re-initiation TNF inhibitor | Relapse after re-initiation |
|---|---|---|---|---|---|---|
[4] | F | IFX/60 | Spinal cord | IFX discontinuation and PSL/resolution | – | |
[5] | M | ADA/24 | Hilar and mediastinal nodes, erythema nodosum | ADA discontinuation and PSL/resolution | – | |
[6] | F | ADA/18 | Mediastinal nodes, nodules on the spleen | ADA continue and PSL/resolution | – | |
[7] | M | IFX/7 | Erythematous skin plaques, bilateral nodular pulmonary infiltrates | IFX continue and topical therapy /resolution of lung, but skin not resolved | – | |
[8] | M | IFX/12 | hilar adenopathies, pulmonary infiltrate | IFX discontinuation/resolution | IFX re-start | |
[9] | M | ADA/60 | Uveitis, mediastinal nodes, mesenterial nodes | ADA discontinuation and PSL/resolution | – | |
M | IFX/72, ADA/18 | Erythema nodosum, mediastinal nodes | ADA discontinuation and PSL/resolution | – | ||
Present case | F | O-IFX 144, IFX-BS 36 | Bilateral pulmonary infiltrates, hilar and mediastinal lymphadenopathy | IFX-BS discontinuation/resolution | – |